Literature DB >> 2405343

Changes in airflow obstruction and oxygen saturation in response to exercise and bronchodilators in cystic fibrosis.

P I Macfarlane1, D Heaf.   

Abstract

The airway response to exercise and inhaled terbutaline was assessed in 25 patients with cystic fibrosis (CF), seeking evidence for the possible deleterious effects of bronchial muscle relaxation. We postulated that "early" and "late" flows, taken from the full maximum expiratory flow volume curve, might move paradoxically in patients with unstable airways. Oxygen saturation was measured continuously; desaturation occurred early in exercise with partial recovery thereafter. This was unrelated to changes in expiratory airflow measurements. Both during and after exercise, and after inhaled bronchodilator, changes in expiratory airflow measurements were strikingly variable. Changes in individual measurements should be interpreted in relationship to the within-subject variability of the test in patients with CF. During exercise, there was a significant increase in mean FEV1; this was most marked in patients with worst lung function. Two patients (both with severe lung disease) showed paradoxical changes in early and late flows. After exercise, only two patients showed the asthmatic pattern of postexercise bronchoconstriction. After inhaled bronchodilator, the group as a whole showed small but statistically significant increases in expiratory airflow measurements. Those with highest baseline FEV1 had the greatest bronchodilator response; this is the opposite of the pattern observed in asthma. Paradox did not occur after bronchodilators and only one patient showed a significant fall in late expiratory airflow. This pattern of expiratory airflow changes is compatible with the concept of airway instability in which any beneficial effects of bronchial tone reduction are canceled out by the effects of compression of damaged airways rendered more compliant by loss of bronchial wall tone. We did not observe any clinically important deleterious effects from this mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405343     DOI: 10.1002/ppul.1950080105

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

Review 1.  Bronchodilators in cystic fibrosis.

Authors:  P L Brand
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 2.  Asthma in cystic fibrosis.

Authors:  Ian M Balfour-Lynn
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 3.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 4.  Exercise recommendations for individuals with cystic fibrosis.

Authors:  S R Boas
Journal:  Sports Med       Date:  1997-07       Impact factor: 11.136

Review 5.  Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.

Authors:  S P Conway; A Watson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

6.  Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline.

Authors:  Brenda M Button; Christine Wilson; Ruth Dentice; Narelle S Cox; Anna Middleton; Esta Tannenbaum; Jennifer Bishop; Robyn Cobb; Kate Burton; Michelle Wood; Fiona Moran; Ryan Black; Summar Bowen; Rosemary Day; Julie Depiazzi; Katherine Doiron; Michael Doumit; Tiffany Dwyer; Alison Elliot; Louise Fuller; Kathleen Hall; Matthew Hutchins; Melinda Kerr; Annemarie L Lee; Christina Mans; Lauren O'Connor; Ranjana Steward; Angela Potter; Tshepo Rasekaba; Rebecca Scoones; Ben Tarrant; Nathan Ward; Samantha West; Dianne White; Lisa Wilson; Jamie Wood; Anne E Holland
Journal:  Respirology       Date:  2016-04-18       Impact factor: 6.424

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.